Vita Life Sciences Limited..

VLS.ASX

Health Care

Market Data

Price

$2.450

+0.0%
Market Cap

$130.2M

P/E Ratio

13.1x

EPS

$0.183

Div. Yield

5.83%

52-Week Change

+0.0%

Latest Earnings

Preliminary Final Report

16 February 2026

Revenue
$93.30
+17.3% YoY
NPAT
$10.40
+18.8% YoY
EPS
$0.19
Dividend
$0.14

Vita Life Sciences delivered strong FY2025 results with record revenue of $93.3M up 17% and net profit of $10.4M up 19%, maintaining its 16th consecutive year of dividend payments at 14.0 cents per share. Malaysia and Singapore operations were standout performers with 35% revenue growth, while China operations faced headwinds from competitive pressures. Key points: Record revenue of $93.3M representing 17% growth driven by brand strength and disciplined execution; Strong dividend track record with 16th consecutive year of payments, declaring 14.0 cents per share (40% increase); Malaysia and Singapore operations delivered standout performance with 35% revenue growth and 62% EBIT increase

Recent Announcements

16 Feb 2026 Actual Results Positive

Preliminary Final Report

Vita Life Sciences delivered strong FY2025 results with record revenue of $93.3M up 17% and net profit of $10.4M up 19%, maintaining its 16th consecutive year of dividend payments at 14.0 cents per share. Malaysia and Singapore operations were standout performers with 35% revenue growth, while China operations faced headwinds from competitive pressures. Key points: Record revenue of $93.3M representing 17% growth driven by brand strength and disciplined execution; Strong dividend track record with 16th consecutive year of payments, declaring 14.0 cents per share (40% increase); Malaysia and Singapore operations delivered standout performance with 35% revenue growth and 62% EBIT increase

Get real-time alerts for VLS

Receive AI-powered earnings summaries and instant notifications when Vita Life Sciences Limited.. releases results.

Register Free